All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Local therapies include topical treatments and phototherapy. Topical medications are typically used as the first-line treatment for most patients with psoriasis affecting <5% body surface area. They may also be used as an adjunctive treatment in patients with more extensive disease. Topical therapies include emollients, corticosteroids, vitamin D analogs, retinoids, and calcineurin inhibitors. Phototherapy (UV irradiation) is recommended as a first-line treatment option in patients with moderate to severe psoriasis, or in those with localized disease but severe symptoms, targeting the hyperproliferative epidermis and T cells.
Save to your areas of interest